These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30052187)

  • 1. Ontario and New Zealand Pharmaceuticals: Cost and Coverage.
    Kelley LT; Tenbensel T; Johnson A
    Healthc Policy; 2018 May; 13(4):23-34. PubMed ID: 30052187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing prices for hospital pharmaceuticals: a successful strategy for New Zealand?
    Tordoff JM; Norris PT; Reith DM
    Value Health; 2005; 8(3):201-8. PubMed ID: 15877592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pricing strategies, executive committee power and negotiation leverage in New Zealand's containment of public spending on pharmaceuticals.
    Main B; Csanadi M; Ozieranski P
    Health Econ Policy Law; 2022 Jul; 17(3):348-365. PubMed ID: 35382921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applying Programme Budgeting Marginal Analysis in the health sector: 12 years of experience.
    Grocott R
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):181-7. PubMed ID: 19402806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand.
    Gleeson D; Lopert R; Reid P
    Health Policy; 2013 Oct; 112(3):227-33. PubMed ID: 23992756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada.
    Morgan SG; Li W; Yau B; Persaud N
    CMAJ; 2017 Feb; 189(8):E295-E302. PubMed ID: 28246223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Price management" and its impact on hospital pharmaceutical expenditure and the availability of medicines in New Zealand hospitals.
    Tordoff JM; Norris PT; Reith DM
    Value Health; 2008 Dec; 11(7):1214-26. PubMed ID: 18489515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-Romanow pharmacare: last-dollar first...first-dollar lost?
    Morgan SG; Willison DJ
    Healthc Pap; 2004; 4(3):10-20. PubMed ID: 15114064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using pharmacoeconomic analysis to make drug insurance coverage decisions.
    Anis AH; Rahman T; Schechter MT
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):119-26. PubMed ID: 10176146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact on health outcome measures of switching to generic medicines consequent to reference pricing: the case of olanzapine in New Zealand.
    Lessing C; Ashton T; Davis PB
    J Prim Health Care; 2015 Jun; 7(2):94-101. PubMed ID: 26125054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Projected cost comparison of selective laser trabeculoplasty versus glaucoma medication in the Ontario Health Insurance Plan.
    Lee R; Hutnik CM
    Can J Ophthalmol; 2006 Aug; 41(4):449-56. PubMed ID: 16883360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PHARMAC measures savings elsewhere to the health sector.
    Metcalfe S; Dougherty S; Brougham M; Moodie P
    N Z Med J; 2003 Mar; 116(1170):U362. PubMed ID: 12658320
    [No Abstract]   [Full Text] [Related]  

  • 13. Projected cost comparison of Trabectome, iStent, and endoscopic cyclophotocoagulation versus glaucoma medication in the Ontario Health Insurance Plan.
    Iordanous Y; Kent JS; Hutnik CM; Malvankar-Mehta MS
    J Glaucoma; 2014 Feb; 23(2):e112-8. PubMed ID: 23807348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How pharmaceutical controls worked in one Ontario hospital.
    McLean WM; Tierney MG
    Can J Hosp Pharm; 1994 Aug; 47(4):176-9. PubMed ID: 10136951
    [No Abstract]   [Full Text] [Related]  

  • 15. Going against the flow: the impact of PHARMAC not funding COX-2 inhibitors for chronic arthritis.
    Grocott R; Metcalfe S
    N Z Med J; 2005 Oct; 118(1223):U1690. PubMed ID: 16224510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Zealand's pharmaceutical reference-pricing strategy may backfire.
    Menkes D
    Lancet; 2000 Feb; 355(9203):558. PubMed ID: 10683017
    [No Abstract]   [Full Text] [Related]  

  • 17. Policy choices for pharmacare; the need to examine benefit design, medication management strategies and evaluation.
    Sketris IS; Brown MG; Murphy AL
    Healthc Pap; 2004; 4(3):36-45; discussion 68-72. PubMed ID: 15114068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fees conflict concluded, concerns of psychotherapists. Will psychotherapy be in short supply?].
    MMW Fortschr Med; 2012 Nov; 154 Spec No 3():20. PubMed ID: 23724709
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharma Pricing & Market Access Europe 2016--Health Network Communications' Tenth Annual Conference (February 23-25, 2016--London, UK).
    D'Souza P
    Drugs Today (Barc); 2016 Mar; 52(3):203-6. PubMed ID: 27186595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.
    Schneeweiss S; Soumerai SB; Maclure M; Dormuth C; Walker AM; Glynn RJ
    Clin Pharmacol Ther; 2003 Oct; 74(4):388-400. PubMed ID: 14534526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.